Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab long-term safety in ulcerative colitis
NCT03648541Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of spesolimab in ulcerative colitis (UC), sponsored by Boehringer Ingelheim. Started Oct 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03648541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648541.